Can a new drug head off multiple myeloma before it starts?
NCT ID NCT06140524
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests an investigational drug called linvoseltamab in people with two precancerous conditions—high-risk MGUS and non-high-risk smoldering multiple myeloma—that raise the risk of developing multiple myeloma. The goal is to see if the drug can eliminate abnormal plasma cells and reduce signs of disease. About 116 participants will receive the drug, and researchers will monitor side effects and how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA (SMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Algemeen Ziekenhuis (AZ) Klina
RECRUITINGBrasschaat, Antwerpen, 2930, Belgium
-
Algemeen Ziekenhuis AZ Delta
RECRUITINGRoeselare, West-Vlaanderen, 8800, Belgium
-
Cork University Hospital
RECRUITINGCork, T12 EC8P, Ireland
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Hospital Clinico Universitario Virgen De La Arrixaca
RECRUITINGEl Palmar, Murcia, 30120, Spain
-
Hospital General Universitario Morales Meseguer
RECRUITINGMurcia, 30008, Spain
-
Hospital Sant Pau
RECRUITINGBarcelona, 08041, Spain
-
Hospital Universitari Mutua Terrassa
RECRUITINGTerrassa, Barcelona, 08221, Spain
-
Hospital Universitario Virgen de las Nieves
RECRUITINGGranada, Andalusia, 18014, Spain
-
Hospital de Cabuenes
RECRUITINGGijón, Principality of Asturias, 33203, Spain
-
Istituto Romagnolo per lo Studio Dei Tumori Dino Amadori
RECRUITINGMeldola, Forli-Cesena, 47014, Italy
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 21287, United States
-
Pratia MCM Krakow
RECRUITINGKrakow, Malopolska, 30-510, Poland
-
San Paolo Hospital
RECRUITINGMilan, Lombardy, 20142, Italy
-
Stony Brook University Hospital
RECRUITINGStony Brook, New York, 11794, United States
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Universitaru Hospital La Princesa
RECRUITINGMadrid, 28006, Spain
-
University of Michigan Health
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
-
Wojewodzki Szpital Zespolony - Ludwik Rydygier Provincial Hospital
RECRUITINGTorun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
Conditions
Explore the condition pages connected to this study.